Innovent Biologics, Inc. (HKG:1801)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Biotechnology	13.04B	9.42B	6.21B	4.56B	4.27B
Total	13.04B	9.42B	6.21B	4.56B	4.27B

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
The People's Republic of China (PRC)	12.07B	8.98B	5.75B	4.13B	3.97B
United States of America ("USA")	380.61M	411.59M	442.60M	411.03M	261.64M
Europe	571.81M	-	-	-	-
Other	19.63M	26.88M	10.12M	12.81M	-
Republic of Indonesia	-	-	-	-	6.60M
Republic of France	-	-	-	-	33.97M
Total	13.04B	9.42B	6.21B	4.56B	4.27B

Data Source: S&P Global Market Intelligence Last updated: Sep 29, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Nov 11, 2026

Data Sources Report a data error